$20.960
-0.574 (-2.74%)Al cierre
Rentabilidad y márgenes de HQL
Evaluating the bottom line, Abrdn Life Sciences Investors maintains a gross margin of 99.06%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 94.87%, while the net margin is 94.87%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively HQL converts its operational activities into shareholder value.
Financials
No data
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.